Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087724 · ClinicalTrials.gov registry record · Phase 2
A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease
A Phase 2 study, sponsored by Astellas Pharma.
- Terminated
- Registry status
- Phase 2
- Development phase
- 510
- Enrollment target
NCT00087724 is a Phase 2 study that was terminated before completion, run by Astellas Pharma. The registered enrollment target is 510 participants.
The verdict
NCT00087724, a Phase 2 study, was terminated before completion, sponsored by Astellas Pharma.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 510 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and efficacy of five fixed dosage levels of FK962 or placebo for 24 weeks in subjects with mild to moderate Alzheimer's disease. Patient visits are every six weeks with limited efficacy measurements at week 6 and 18.
Interventions
- DRUG FK962
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 510 participants |
| Start Date | 2004-07 |
| Est. Completion | 2006-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00087724
The ClinicalTrials.gov registry entry for NCT00087724 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 510 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which FK962 is the first listed.
NCT00087724 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00087724 about?
NCT00087724 is a clinical study titled "A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease". The purpose of this study is to evaluate the safety and efficacy of five fixed dosage levels of FK962 or placebo for 24 weeks in subjects with mild to moderate Alzheimer's disease. Patient visits are every six weeks with limited efficacy measurements at week 6 and 18.
What is the current status of trial NCT00087724?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 510 participants. The study started on 2004-07. Estimated completion is 2006-09.
What interventions are being tested in trial NCT00087724?
The interventions under investigation include: FK962 (DRUG).
Who is sponsoring clinical trial NCT00087724?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.